ストックスクリーナーアプリを入手
3.72
1.09%
0.04
前日終値:
$3.68
開ける：
$3.7
24時間の取引高:
385.45K
Relative Volume:
0.34
時価総額：
$276.13M
収益：
$6.96M
当期純損益:
$-46.51M
株価収益率:
-21.68
EPS:
-0.1716
ネットキャッシュフロー:
$-37.99M
1週間 パフォーマンス:
-4.37%
1か月 パフォーマンス:
-6.53%
6か月 パフォーマンス:
+18.47%
1年 パフォーマンス:
-69.05%
1日の値動き範囲:
$3.625
$3.725
1週間の範囲:
$3.47
$3.94
52週間の値動き範囲:
$1.60
$16.55
Perspective Therapeutics Inc Stock (CATX) Company Profile
名前
Perspective Therapeutics Inc
セクター
電話
509-375-1202
住所
350 Hills Street, Suite 106, Richland
CATX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
3.72 | 273.16M | 6.96M | -46.51M | -37.99M | -0.1716 |
|
ABT
Abbott Laboratories
|
131.36 | 233.71B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.75 | 152.83B | 18.49B | 2.51B | 3.23B | 1.68 |
|
SYK
Stryker Corp
|
376.67 | 144.35B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.74 | 119.00B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.16 | 46.00B | 5.69B | 4.14B | 577.90M | 6.96 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-13 | 開始されました | H.C. Wainwright | Buy |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-11-25 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-10-01 | 開始されました | Wedbush | Outperform |
| 2024-09-25 | 開始されました | Truist | Buy |
| 2024-07-25 | 開始されました | BofA Securities | Buy |
| 2024-05-09 | 開始されました | Cantor Fitzgerald | Overweight |
すべてを表示
Perspective Therapeutics Inc (CATX) 最新ニュース
Multi factor analysis applied to Perspective Therapeutics Inc.Free Value Investing Picks With Stability - Newser
Perspective Therapeutics, Inc. shares rise 3.09% after-hours following a corporate update on clinical progress and strategic positioning. - AInvest
Published on: 2025-08-04 12:18:12 - Jammu Links News
When is Perspective Therapeutics Inc. stock expected to show significant growthInvest smarter with expert stock recommendations - Jammu Links News
Why is Perspective Therapeutics Inc. stock attracting strong analyst attentionConsistent triple returns - Jammu Links News
What are the technical indicators suggesting about Perspective Therapeutics Inc.Unlock your portfolio’s hidden potential - Jammu Links News
How does Perspective Therapeutics Inc. generate profit in a changing economyBuild wealth steadily with proven methods - Jammu Links News
What are the latest earnings results for Perspective Therapeutics Inc.Unlock rapid growth potential in your portfolio - Jammu Links News
How many analysts rate Perspective Therapeutics Inc. as a “Buy”Build a strong portfolio for long-term success - Jammu Links News
Perspective Therapeutics: Giving Us Some Valuable Perspective On Alpha Emitter Therapy - Seeking Alpha
Perspective Therapeutics (NYSE:CATX) vs. Motus GI (NASDAQ:MOTS) Critical Contrast - Defense World
How to read the order book for Perspective Therapeutics Inc.Secure Asset Flow and Trend Pattern Analysis - Newser
Perspective Therapeutics Updates Radiopharmaceutical Platform Presentation - TipRanks
Live market analysis of Perspective Therapeutics Inc.Predictive AI Engine for Smart Investing - Newser
Applying chart zones and confluence areas to Perspective Therapeutics Inc.Short-Term AI-Based Stock Price Forecast - Newser
What makes Perspective Therapeutics Inc. stock price move sharplySwing Candidate List with Trade Cues - Newser
When is the best time to exit Perspective Therapeutics Inc.Smart Trade Mapping with Entry Details - Newser
How strong is Perspective Therapeutics Inc. company’s balance sheetTop Growth Tips For Consistent Profits - jammulinksnews.com
Perspective Therapeutics Inc. Earnings Report Breakdown: What Investors Should KnowAI Driven Buy Alert Trade Blueprint Released - metal.it
Volume spikes in Perspective Therapeutics Inc. stock – what they meanSector Rotation Outlook With Historical Summary - Newser
Is It Too Late to Sell Perspective Therapeutics Inc.Watchlist for Smart Swing Trading Updated - metal.it
Perspective Therapeutics shares fall 3.16% intraday after FDA approval conference call for Sephience. - AInvest
Is Perspective Therapeutics Inc. the Top Chart Pick This WeekCommunity Strategy With High Win Rate Backtested - metal.it
How volatile is Perspective Therapeutics Inc. stock compared to the marketFinancial News Outlook For 2025 - jammulinksnews.com
Is it the right time to buy Perspective Therapeutics Inc. stockAI Powered Target Finder For Consistent Profits - Jammu Links News
What is the dividend policy of Perspective Therapeutics Inc. stockStock Market Review That Work - Jammu Links News
Perspective Therapeutics shares fall 1.48% premarket after Unicycive Therapeutics receives FDA CRL. - AInvest
Volume spikes in Perspective Therapeutics Inc. stock – what they mean Asset Growth Pattern and Return Summary - Newser
What is the risk reward ratio of investing in Perspective Therapeutics Inc. stockInvest with confidence backed by data - Jammu Links News
Published on: 2025-07-27 16:42:40 - Jammu Links News
Perspective Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayFree Predictions - Newser
Moving Average Trends for Perspective Therapeutics Inc. Stock: What They IndicateSmart High Yield Swing Trades - Newser
How Perspective Therapeutics Inc. stock performs during market volatilityFree Real-Time Trading Opportunities - Newser
What analysts say about Perspective Therapeutics Inc. stockTriple returns potential - PrintWeekIndia
What drives Perspective Therapeutics Inc. stock priceBreakthrough financial growth - PrintWeekIndia
Is Perspective Therapeutics Inc. a good long term investmentFree Buy/Sell Signal Notifications - Autocar Professional
Should I buy Perspective Therapeutics Inc. stock before earningsOutstanding capital returns - Jammu Links News
Perspective Therapeutics Inc (CATX) 財務データ
収益
当期純利益
現金流量
EPS
Perspective Therapeutics Inc (CATX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Spoor Johan M. | Chief Executive Officer |
Mar 28 '25 |
Buy |
2.21 |
4,650 |
10,288 |
4,650 |
| Williamson Robert F III | Director |
Mar 31 '25 |
Buy |
2.14 |
38,145 |
81,775 |
108,982 |
| Williamson Robert F III | Director |
Mar 28 '25 |
Buy |
2.27 |
22,192 |
50,376 |
70,837 |
| Graham Juan | Chief Financial Officer |
Mar 28 '25 |
Buy |
2.25 |
33,333 |
74,946 |
35,354 |
| Woods Lori A | Director |
Mar 31 '25 |
Buy |
2.13 |
23,475 |
49,999 |
183,460 |
| HENSON HEIDI | Director |
Dec 04 '24 |
Buy |
3.85 |
25,975 |
100,004 |
25,975 |
| Spoor Johan M. | CEO |
Dec 04 '24 |
Buy |
3.77 |
8,000 |
30,132 |
36,257 |
| Williamson Robert F III | Director |
Nov 25 '24 |
Buy |
3.64 |
6,266 |
22,814 |
430,058 |
| Hunt Jonathan Robert | Chief Financial Officer |
Nov 25 '24 |
Buy |
3.82 |
12,829 |
48,974 |
48,800 |
| Spoor Johan M. | CEO |
Nov 25 '24 |
Buy |
3.78 |
14,500 |
54,868 |
152,072 |
0.74%
1.39%
大文字化:
|
ボリューム (24 時間):